OptimizeRx Corp. OPRX 深 沪
已收盘 08-01 16:00:00 美东时间
12.50
-0.120
-0.95%
华盛通- 最 高13.0352
- 今 开12.45
- 成交量 23.18万股
- 最 低 12.01
- 昨 收 12.62
- 总市值 2.31亿
- 52周最高 15.71
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 3.78
- 委 比 -78.47%
- 总股本 1849.51万
- 历史最高 99.178
- 量 比 1.21
- 振 幅 8.12%
- 历史最低 3.78
- 每 手 1
- 风险率 3.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
OptimizeRx Corp. will host a conference call on August 7, 2025, at 4:30 p.m. Eastern Time, to discuss its second quarter 2025 financial results. The call will feature OptimizeRx management and include a Q&A session. Details to join the call or webcast are provided, along with instructions to dial in or log on five minutes prior to the start. A replay will be available for 12 months on the company's website. OptimizeRx is a healthcare technology c...
07-17 11:30
A Look Ahead: Simulations Plus's Earnings Forecast
Simulations Plus (NASDAQ:SLP) is gearing up to announce its quarterly earnings ...
07-11 22:01
OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors
OptimizeRx Corp. announced on June 24, 2025, that Steve Silvestro, currently serving as CEO, has been appointed to its Board of Directors, effective June 20, 2025. Silvestro joined the Company in 2019 and became CEO in March 2025 after serving as interim CEO since January 2025. His appointment is expected to enhance leadership and support the Company’s strategic initiatives to deliver value for customers and shareholders. Silvestro expressed his ...
06-24 11:30
OptimizeRx And Simulmedia Join Forces To Enable Real-Time, Data-Driven TV Advertising For Life Sciences With Privacy-Forward Audience Targeting
Strategic Collaboration Brings Precision Micro-Neighborhood Targeting Healthcare Consumer Audiences to Linear and Connected TV
06-18 15:39
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
美股大行评级 | eToro Group获多家大行首予买入评级，甲骨文获多家机构上调目标价
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持PolyPid(PYPD)"买入"评级，目标价从11美元升至13美元</p> <p>• HC Wainwright & Co.：维持Vertical Aerosp
06-10 09:45
Stifel Maintains Buy on OptimizeRx, Raises Price Target to $16
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $12.5 to $16.
06-10 01:45
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Stifel Maintains Buy on OptimizeRx, Raises Price Target to $12.5
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $8 to $12.5.
05-14 00:26
